Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ (2016) 0.79

Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clin Res Cardiol (2016) 0.75

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA (2001) 24.12

Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74

A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest (2009) 14.06

Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med (2015) 5.29

Acute stroke intervention: a systematic review. JAMA (2015) 2.66

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29

Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med (2015) 2.27

Effect of Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning-the DANTE Study Leiden: A Randomized Clinical Trial. JAMA Intern Med (2015) 2.15

Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ (2015) 1.85

Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol (2015) 1.69

Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol (2011) 1.50

Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging (2009) 1.45

Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36

Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med (2014) 1.21

Atrial fibrillation follow-up investigation of rhythm management -- the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol (1997) 1.17

A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace (2013) 1.16

Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost (2013) 1.02

Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians. JAMA (2015) 1.00

Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med (2011) 0.95

Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ (2015) 0.86

Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol (2015) 0.83

Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med (2014) 0.77

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging (2015) 0.76